Thalidomide for recurrent renal-cell cancer in a 40-year-old man

ONCOLOGY

Volumn 14, Issue 12 SUPPL. 13, 2000, Pages 33-36

  Amato, Robert ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; FLUOROURACIL; INTERLEUKIN 2; THALIDOMIDE;

ADENOCARCINOMA; ADULT; ARTICLE; CASE REPORT; DRUG COMBINATION; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METASTASIS; PILOT STUDY; RECURRENT DISEASE;

ADENOCARCINOMA, CLEAR CELL; ADULT; ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; DRUG THERAPY, COMBINATION; FLUOROURACIL; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; NEOPLASM METASTASIS; PILOT PROJECTS; RECURRENCE; THALIDOMIDE;

EID: 0034574258     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Landis SH, Murray T, Bolden S, et al: Cancer statistics, 1999. CA Cancer J Clin 49:8-31, 1999.
2. Stadler WM, Vogelzang NJ: Low-dose interleukin-2 in the treatment of metastatic renal cell carcinoma. Semin Oncol 22:67-73, 1995.
3. Hawkins MJ: Immunotherapy with high-dose interleukin-2, in Vogelzang NJ, Scardino PT, Shipley WU, et al (eds): Comprehensive Text-book of Genital Urinary Oncology, pp 242-247. Baltimore, Williams & Wilkins, 1996.
4. Minasian LM, Motzer RJ, Cluck L, et al: Interferon alpha 2A in advanced renal cell carcinoma: Treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 11:1368-1375, 1993.
5. Negrier S, Escudier D, Lasset C, et al: Recombinant human interleukin-2, recombinant human interferon alpha 2A or both in metastalic renal cell carcinoma. N Engl J Med 338:1272-1278, 1998.
6. Chapman AE, Goldstein LJ: Multiple drug resistance: Biologic basis and clinical significance in renal cell carcinoma. Semin Oncol 22:17-28, 1995.
7. Kim WJ, Kakehi Y, Kinoshita H, et al: Expression patterns of multidrug-resistance (MDRI), multidrug resistance-associated protein (MRP), glutathione-S-transferase-pi (GST-pi) and DNA topoisomerase II (Topo II) genes in renal cell carcinomas in normal kidney. J Urol 156:506-511,1996.
8. Battekay EJ: Angiogenesis: Mechanistic insights, neovascular disease, and therapeutic prospects. J Mol Med 73:333-346, 1995.
9. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Natl Med 1:27-31, 1995.
10. D'Amato RJ, Loughnan MS, Flynn E, et al: Thalidomide is an inhibitor of angiogenesis. Pro Natl Acad Sci USA 91:4082-4085, 1994.
11. Kenyon BM, Browne F, D'Amato RJ: Affects of thalidomide and related metabolists in a mouse corneal model of neovascularization. Exp Eye 64:971-978, 1997.
12. Sampaio EP, Sarno EN, Galill YR, et al: Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173:669-703, 1991.
13. Corral LJ, Mueller GW, Moreira AL, et al: Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol Med 2:506-515, 1996.
14. Haslett PAJ, Corral LJ, Albert M, et al: Thalidomide co-stimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CDA positive subset. J Exp Med 187:1885-1892, 1998.